Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027

October 2018 | 120 pages | ID: D8445E453428EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight’s ‘Down Syndrome - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Down Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Down syndrome from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Down syndrome - Disease Understanding and Treatment Algorithm

The DelveInsight Down Syndrome market report gives the thorough understanding of the Down syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Down syndrome in the US, Europe, and Japan.

Down syndrome Epidemiology

The Down syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic – transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).

According to DelveInsight, the prevalent cases of Down syndrome was 541,538 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Down syndrome with 258,502 prevalent cases in 2016. In 7MM, males had highest prevalent cases of DS as compared to females in 2016. This trend is expected to increase during the study period

Down syndrome Drug Chapters

This segment of the Down syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.

Down syndrome Market Outlook

The Down syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Down syndrome market is expected to grow during the forecasted period of 2018-2027 owing to the launch of few drugs (presently in Phase III and Phase II). Down syndrome therapeutics market has seen a 7MM sales of USD 1621.40 Million in 2016.

Down syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Down syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Down syndrome Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Down syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Down syndrome market
• Organize sales and marketing efforts by identifying the best opportunities for Down syndrome market
• To understand the future market competition in the Down syndrome market.

Contents

1. KEY INSIGHTS

2. DOWN SYNDROME: MARKET OVERVIEW AT A GLANCE

2.1. Total Market Share (%) Distribution of Down syndrome in 2016
2.2. Total Market Share (%) Distribution of Down syndrome in 2027

3. DOWN SYNDROME: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Types of Down syndrome
3.3. Etiopathogenesis
3.4. Phenotypic Variability of Down syndrome
3.5. Metabolic Imbalance in Down syndrome
3.6. Clinical Conditions Associated with Down syndrome
3.7. Symptoms of Down syndrome
3.8. Risk factors for Down syndrome
3.9. Genetics Basis of Down syndrome
  3.9.1. Gene expression variation
3.10. Diagnosis of Down syndrome

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Diagnosed Prevalent Population of Down syndrome in 7MM

5. COUNTRY WISE-EPIDEMIOLOGY OF DOWN SYNDROME

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Total Diagnosed Prevalent Cases of Down syndrome in the United States
  5.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the United States
  5.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the United States
  5.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the United States
  5.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the United States
5.2. EU5 Countries
5.3. Germany
  5.3.1. Assumptions and Rationale
  5.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Germany
  5.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Germany
  5.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Germany
  5.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Germany
  5.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany

6. FRANCE

  6.1.1. Assumptions and Rationale
  6.1.2. Total Diagnosed Prevalent Cases of Down syndrome in France
  6.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in France
  6.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in France
  6.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in France
  6.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France
6.2. Italy
  6.2.1. Assumptions and Rationale
  6.2.2. Total Diagnosed Prevalent Cases of Down syndrome in Italy
  6.2.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Italy
  6.2.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Italy
  6.2.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Italy
  6.2.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy
6.3. Spain
  6.3.1. Assumptions and Rationale
  6.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Spain
  6.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Spain
  6.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Spain
  6.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Spain
  6.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain
6.4. United Kingdom
  6.4.1. Assumptions and Rationale
  6.4.2. Total Diagnosed Prevalent Cases of Down syndrome in the UK
  6.4.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the UK
  6.4.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the UK
  6.4.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the UK
  6.4.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK
6.5. Japan
  6.5.1. Assumptions and Rationale
  6.5.2. Total Diagnosed Prevalent Cases of Down syndrome in Japan
  6.5.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Japan
  6.5.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Japan
  6.5.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Japan
  6.5.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan

7. CURRENT TREATMENT PRACTICES

7.1. Management Guidelines
  7.1.1. American College of Obstetricians and Gynecologists
  7.1.2. Health Care Guidelines for People with Down syndrome: European Down Syndrome Association

8. UNMET NEEDS

9. EMERGING THERAPIES

9.1. Key Cross Competition
9.2. Aricept: Eisai
  9.2.1. Product Description
  9.2.2. Other Developmental Activities
  9.2.3. Clinical Development
  9.2.4. Clinical Trials Information
  9.2.5. Product Profile
9.3. ELND005: Transition Therapeutics Ireland Limited
  9.3.1. Product Description
  9.3.2. Other Developmental Activities
  9.3.3. Clinical Development
  9.3.4. Clinical Trials Information
  9.3.5. Safety and Efficacy
  9.3.6. Product Profile
9.4. Pentylenetetrazole: Balance Therapeutics
  9.4.1. Product Description
  9.4.2. Other Developmental Activities
  9.4.3. Clinical Development
  9.4.4. Clinical Trials Information
  9.4.5. Product Profile
9.5. ACI-24: AC Immune
  9.5.1. Product Description
  9.5.2. Other Developmental Activities
  9.5.3. Clinical Development
  9.5.4. Clinical Trials Information
  9.5.5. Safety and Efficacy
  9.5.6. Product Profile

10. DOWN SYNDROME: 7 MAJOR MARKET ANALYSIS

10.1. Key Findings
10.2. Market Size of Down syndrome in 7MM

11. THE UNITED STATES MARKET OUTLOOK

11.1. United States Market Size
  11.1.1. Total Market size of Down syndrome in the United States
11.2. EU-5 Countries: Market Outlook
11.3. Germany
  11.3.1. Total Market size of Down syndrome in Germany
11.4. France
  11.4.1. Total Market Size of Down Syndrome in France
11.5. Italy
  11.5.1. Total Market Size of Down Syndrome in Italy
11.6. Spain
  11.6.1. Total Market size of Down syndrome in Spain
11.7. United Kingdom
  11.7.1. Total Market Size of Down Syndrome in the United Kingdom

12. JAPAN: MARKET OUTLOOK

12.1. Japan
  12.1.1. Total Market Size of Down Syndrome in Japan

13. MARKET DRIVERS

14. MARKET BARRIERS

15. APPENDIX

15.1. Report Methodology

16. DELVEINSIGHT CAPABILITIES

17. DISCLAIMER

18. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent Patient Population of Down Syndrome in 7MM (2016-2027)
Table 2: Total Diagnosed Prevalent Cases of Down Syndrome in the United States (2016-2027)
Table 3: Type-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 4: Sex-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 5: Age-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Table 6: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the US (2016-2027)
Table 7: Total Diagnosed Prevalent Cases of Down Syndrome in Germany (2016-2027)
Table 8: Type-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 9: Sex-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 10: Age-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Table 11: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany (2016-2027)
Table 12: Total Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 13: Total Diagnosed Prevalent Cases of Down Syndrome in France (2016-2027)
Table 14: Type-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 15: Sex-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 16: Age-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Table 17: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France (2016-2027)
Table 18: Total Diagnosed Prevalent Cases of Down Syndrome in Italy (2016-2027)
Table 19: Type-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 20: Sex-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 21: Age-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Table 22: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy (2016-2027)
Table 23: Total Diagnosed Prevalent Cases of Down Syndrome in Spain (2016-2027)
Table 24: Type-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 25: Sex-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 26: Age-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Table 27: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain (2016-2027)
Table 28: Total Diagnosed Prevalent Cases of Down Syndrome in the UK (2016-2027)
Table 29: Type-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 30: Sex-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 31: Age-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Table 32: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK (2016-2027)
Table 33: Total Diagnosed Prevalent Cases of Down Syndrome in Japan (2016-2027)
Table 34: Type-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 35: Sex-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 36: Age-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Table 37: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan (2016-2027)
Table 38: Market Size of Down Syndrome in 7MM in USD Million (2016-2027)
Table 39: US Market Size of Down Syndrome in USD Million (2016-2027)
Table 40: Market Size of Down Syndrome in Germany, USD Millions (2016-2027)
Table 41: Market Size of Down Syndrome in France, USD Millions (2016-2027)
Table 42: Market Size of Down Syndrome in Italy, USD Millions (2016-2027)
Table 43: Market Size of Down Syndrome in Spain, USD Millions (2016-2027)
Table 44: Market Size of Down Syndrome in the UK USD Millions (2016-2027)
Table 45: Market Size of Down Syndrome in Japan, USD Millions (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Types of Down syndrome
Figure 2: Comparison of balance translocation and translocation DS Karyotype
Figure 3: Comparison of normal and non-disjunction DS Karyotype
Figure 4: Types of Down syndrome
Figure 5: Clinical conditions associated with Down syndrome
Figure 6: Risk Factors for Down syndrome
Figure 7: Candidate dosage sensitive genes on chromosome 21causing DS phenotype
Figure 8: Karyotyping for diagnosis of Down syndrome
Figure 9: Common techniques used for diagnosis of Down’s syndrome along with its advantages and disadvantages
Figure 10: Total Prevalent Patient Population of Down Syndrome in 7MM (2016-2027)
Figure 11: Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 12: Type-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 13: Sex-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 14: Age-specific Diagnosed Prevalence of Down Syndrome in the United States (2016-2027)
Figure 15: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the US (2016-2027)
Figure 16: Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 17: Type-specific Diagnosed Prevalence of Down Syndrome in the Germany (2016-2027)
Figure 18: Sex-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 19: Age-specific Diagnosed Prevalence of Down Syndrome in Germany (2016-2027)
Figure 20: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany (2016-2027)
Figure 21: Total Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 22: Type-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 23: Sex-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 24: Age-specific Diagnosed Prevalence of Down Syndrome in France (2016-2027)
Figure 25: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France (2016-2027)
Figure 26: Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 27: Type-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 28: Sex-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 29: Age-specific Diagnosed Prevalence of Down Syndrome in Italy (2016-2027)
Figure 30: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy (2016-2027)
Figure 31: Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 32: Type-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 33: Sex-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 34: Age-specific Diagnosed Prevalence of Down Syndrome in Spain (2016-2027)
Figure 35: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain (2016-2027)
Figure 36: Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 37: Type-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 38: Sex-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 39: Age-specific Diagnosed Prevalence of Down Syndrome in the UK (2016-2027)
Figure 40: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK (2016-2027)
Figure 41: Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 42: Type-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 43: Sex-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 44: Age-specific Diagnosed Prevalence of Down Syndrome in Japan (2016-2027)
Figure 45: Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan (2016-2027)
Figure 46: Unmet needs for DS
Figure 47: Emerging Drugs Analysis
Figure 48: Aricept, Clinical Trial Description, 2018
Figure 49: ELND005, Clinical Trial Description, 2018
Figure 50: BTD-001, Clinical Trial Description, 2018
Figure 51: ACI-24, Clinical Trial Description, 2018
Figure 52: Market Size of Down Syndrome in 7MM in USD Million (2016-2027)
Figure 53: Market Size of Down Syndrome in the US, USD Millions (2016-2027)
Figure 54: Market Size of Down Syndrome in Germany, USD Millions (2016-2027)
Figure 55: Market Size of Down Syndrome in France, USD Millions (2016-2027)
Figure 56: Market Size of Down Syndrome in Italy, USD Millions (2016-2027)
Figure 57: Market Size of Down Syndrome in Spain, USD Millions (2016-2027)
Figure 58: Market Size of Down Syndrome in the UK, USD Millions (2016-2027)
Figure 59: Market Size of Down Syndrome in Japan, USD Millions (2016-2027)
Figure 60: Market Drivers
Figure 61: Market Barriers